Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wai Yuen Tong Medicine Holdings (HKSE:00897) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Wai Yuen Tong Medicine Holdings ROE % Related Terms
Wai Yuen Tong Medicine Holdings ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a ROE % of 0.21% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #631 out of 934 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Wai Yuen Tong Medicine Holdings' ROE % too high?
Wai Yuen Tong Medicine Holdings' current ROE % is 0.21%. The Drug Manufacturers industry median ROE % is 6.22. Wai Yuen Tong Medicine Holdings' value of 0.21% is 96.6% below this industry median. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #631 out of 934 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #631 out of 934 companies for ROE %. This places Wai Yuen Tong Medicine Holdings in the lower half of its industry. The industry median ROE % is 6.22. Wai Yuen Tong Medicine Holdings' value of 0.21% is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.22, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wai Yuen Tong Medicine Holdings's current ROE % of 0.21% is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wai Yuen Tong Medicine Holdings's current ROE % is 0.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.29 — trading right at its estimated fair value. The current ROE % is 0.21% and 96.6% below the Drug Manufacturers industry median of 6.22. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current ROE % is 0.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be undervalued.
The current stock price of HK$0.29 is trading 0% below its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Fairly Valued.
Key valuation signals for HKSE:00897:
ROE %: 0.21%
GF Value™: HK$0.29 vs. price of HK$0.29 (0% below fair value)
Industry Position: 96.6% below the Drug Manufacturers median (#631 of 934)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
38GF Score
Get the complete analysis for HKSE:00897
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
